Adherence Gaps in Serious Mental Illness — Missed pills, not failed molecules, drive most psychotic relapse. A September 2026 Psychiatric Times report found that fewer than one in five young patients with first-episode psychosis adhere to antipsychotic therapy, and every relapse brings readmission costs that payers now track closely. U.S. Medicaid analyses link second-generation long-acting antipsychotics to lower inpatient use than oral therapy, which has moved depots earlier in treatment guidelines. Johnson & Johnson's paliperidone palmitate franchise, Otsuka and Lundbeck's aripiprazole depots and Teva's Uzedy all compete for that earlier start. Teva's October 2026 approval of WELTRUZA adds once-monthly subcutaneous olanzapine without the post-injection monitoring that held back the older intramuscular product. The result is a psychiatric pool worth USD 4,258.4 Mn in 2025, the largest therapeutic area in this report. Structurally, this turns adherence from a clinical problem into a product feature that payers will fund.
Long-Acting Injectable Pharmaceuticals Market Size, Share & Growth
Long-Acting Injectable Pharmaceuticals Market by Product Type (Microspheres, In-Situ Forming Depots/Gels, Implants, Suspensions), by Therapeutic Area (Psychiatric Disorders, Contraception, Oncology, Infectious Disease, Ophthalmology, endocrinology and metabolic disease), by Technology (PLGA-Based, Non-PLGA Polymer-Based, Non-Polymeric (Implant), Oil-based depot and crystal suspension technologies), by End User (Hospitals, Specialty Pharmacies, Homecare Settings, Correctional & Public Health Facilities), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035
Long-Acting Injectable Pharmaceuticals Industry Perspective
The Global Long-Acting Injectable Pharmaceuticals Market was valued at USD 12,642.7 Mn in 2025 and is projected to reach USD 35,129.3 Mn by 2035, growing at a CAGR of 10.76% during the forecast period 2026–2035, according to Vectomat Insights.
Psychiatric disorders form the largest therapeutic pool at 33.7% of 2025 revenue, yet the structural shift is toward ever-longer dosing intervals, and implants, forecast at 15.1% a year, are the clearest expression of it.
Long-Acting Injectable Pharmaceuticals Market: Overview
Long-Acting Injectable Pharmaceuticals Market encompasses sustained-release drug products that maintain therapeutic levels for one week to five years from a single administration. The scope covers four product types (microspheres, in-situ forming depots and gels, implants and suspensions), four technology families from PLGA polymers to oil-based and crystal suspensions, and therapeutic use across psychiatry, contraception, oncology, infectious disease and endocrine, ophthalmic and metabolic conditions.
The value chain runs in three tiers. Foundational technology providers such as Medincell, Camurus and Lupin own the polymer, lipid and microsphere platforms. Specialist developers, including Johnson & Johnson, Gilead Sciences and Teva Pharmaceuticals, take molecules through approval and sell branded depots. Application-layer specialists such as Foresee Pharmaceuticals reformulate established hormone depots into ready-to-use formats for clinics.
For procurement and investment decision-makers, the live question is which formats and dosing intervals capture value, not whether the category grows. This report provides sub-segment data across four segmentation dimensions, country-level analysis across 35+ countries and competitive profiles of 14 companies.
According to World Health Organization, 2025-07-14, WHO recommended injectable lenacapavir as an additional HIV prevention option in July 2025, describing it as a long-acting antiretroviral shown in trials to prevent almost all HIV infections among people at risk, which places twice-yearly dosing inside global prevention guidelines.

Key Insights
- The market is projected to grow from USD 12,642.7 Mn in 2025 to USD 35,129.3 Mn by 2035 at a 10.76% CAGR, according to Vectomat Insights.
- Microspheres are the dominant product type at 32.0% of 2025 revenue (USD 4,045.7 Mn).
- Implants are the fastest-growing product type, forecast to compound at 15.1% a year to USD 11,348.3 Mn by 2035.
- Psychiatric disorders are the dominant therapeutic area at 33.7% of revenue, because depots address the missed-dose problem behind most schizophrenia relapse.
- Hospitals are the dominant end user at 43.7% of 2025 revenue, since most initiation doses and implant insertions need trained staff.
- North America leads regionally with a 39.0% share (USD 4,930.7 Mn); the U.S. alone accounts for USD 3,944.6 Mn.
- Asia Pacific is the fastest-growing region, with South Korea expanding at a 13.0% CAGR and Japan at 11.1%.
- Platform licensing is reshaping competition: Medincell's copolymer depot sits behind Teva's 2026 WELTRUZA approval and Camurus has licensed FluidCrystal to Eli Lilly.
- PLGA-based formulations are forecast to lift their share from 47.4% to 62.7% of revenue by 2035 as monthly and longer metabolic depots reach the market.

Long-Acting Injectable Pharmaceuticals Market: Report Scope
| Report Name | Long-Acting Injectable Pharmaceuticals Market by Product Type (Microspheres, In-Situ Forming Depots/Gels, Implants, Suspensions), by Therapeutic Area (Psychiatric Disorders, Contraception, Oncology, Infectious Disease, Ophthalmology, endocrinology and metabolic disease), by Technology (PLGA-Based, Non-PLGA Polymer-Based, Non-Polymeric (Implant), Oil-based depot and crystal suspension technologies), by End User (Hospitals, Specialty Pharmacies, Homecare Settings, Correctional & Public Health Facilities), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035 |
|---|---|
| Market Size in 2025 | USD 12,642.7 Mn (2025) |
| Market Forecast in 2035 | USD 35,129.3 Mn (2035) |
| Growth Rate (CAGR) | 10.76% |
| Historical Data Period | 2023–2025 |
| Base Year | 2025 |
| Forecast Period | 2026–2035 |
| Number of Pages | 300+ |
| Tables & Figures | 98 tables & 71 figures |
| Report Code | VMI-1-1-27807 |
| Report Format | |
| Delivery Format | Electronic (PDF), Excel add-on available on request |
| Published Date | November 2026 |
| Research Methodology | Primary interviews + secondary research + verified market sizing (top-down and bottom-up triangulation) |
| Key Companies Covered | Johnson & Johnson, Otsuka Pharmaceutical, Teva Pharmaceuticals, Gilead Sciences, ViiV Healthcare, Pfizer, Organon, Alkermes, Indivior, Ipsen, Camurus, Medincell, Foresee Pharmaceuticals, Lupin |
| Segments Covered | Product Type, Therapeutic Area, Technology, End User |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, The Middle East, Africa |
| Customization Scope | Up to 10% free customization on top of the standard report scope. Available on request — additional segments, geographies, molecules, or extended forecast periods |
The VMI Advantage: Long-Acting Injectable Pharmaceuticals Market Report
Decision-makers comparing market intelligence reports on Long-Acting Injectable Pharmaceuticals will find the VMI report differentiated on the following dimensions.
| Dimension | VMI Report | Industry Average |
|---|---|---|
| Report Pages | 300+ | ~120 pages |
| Forecast Horizon | 10 years | 7 years |
| Segmentation Dims | 4 dims | 4-5 dimensions |
| Historical Data | 3 years | 4-5 years |
| Country Coverage | 35+ countries | 15-18 countries |
| Companies Profiled | 14 companies | 10-12 companies |
| DROC Framework | Full (4 elem) | Drivers only |
For custom scope — additional segments, specific geographies, or extended forecast periods — contact sales@vectomatinsights.com
Key Factors Propelling the Long-Acting Injectable Pharmaceuticals Market
Twice-Yearly HIV Prevention Scale-Up — HIV prevention has become the market's highest-profile volume story. The FDA approved Gilead's Yeztugo (lenacapavir) in June 2025 as the first PrEP option dosed once every six months, and the European Commission followed with Yeytuo in August 2025. WHO recommended injectable lenacapavir in July 2025, which unlocked procurement by donor programs. The Global Fund and PEPFAR have each committed to reach up to 2 million people, and first shipments landed in Eswatini and Zambia in November 2025. ViiV Healthcare is answering with ultra-long-acting cabotegravir work aimed at four-month dosing or longer. Infectious disease earns USD 1,770.0 Mn in 2025 and is forecast to grow at 11.62% a year, and that pace should hold as access programs mature.
Longer Dosing Interval Approvals — Each extra month between doses is a competitive weapon. In January 2026 the FDA extended Organon's NEXPLANON implant to five years of use, two years beyond its earlier label, and in August 2025 it approved Foresee's CAMCEVI ETM 21 mg as a ready-to-use three-month leuprolide depot. Otsuka and Lundbeck's Abilify Asimtufii, dosed every two months, gained Health Canada approval in January 2025. Fewer visits cut clinic load and lower the chance that a patient drops out of care. Longer-interval formats also reset the patent clock for franchises facing generics. Implants, the format with the longest intervals, are forecast to grow at 15.1% a year, the fastest of any product type.
Long-Acting Obesity and Metabolic Pipelines — Obesity is pulling long-acting technology into its largest new category. Weekly GLP-1 injections proved the demand; monthly and longer versions are the next commercial target. Pfizer completed its acquisition of Metsera in November 2025, adding a monthly injectable GLP-1 candidate, and Camurus signed a collaboration and license agreement with Eli Lilly in June 2025 to apply its FluidCrystal depot to incretins. In South Korea, G2GBio licensed long-acting semaglutide microsphere technology with investment from Samsung Bioepis's Epis NexLab. These deals sit inside the ophthalmology, endocrinology and metabolic disease segment, the fastest-growing therapeutic area at a 16.46% CAGR. Camurus's Lilly agreement is the clearest sign that platform owners will capture part of that value.
This is a historic day in the decades-long fight against HIV.
WELTRUZA brings the efficacy of olanzapine to a once-monthly subcutaneous injection without the post-injection monitoring that limited earlier long-acting olanzapine, extending Teva's long-acting franchise alongside UZEDY.
Key Headwinds Facing the Long-Acting Injectable Pharmaceuticals Market
Premium Pricing and Access Pushback — Long-acting formats carry premium prices, and buyers are pushing back. Gilead's Yeztugo launched in the United States at a list price reported at about USD 28,218 a year, and UNAIDS Executive Director Winnie Byanyima publicly urged the company to lower it. Similar tension shows up in psychiatry, where advocacy groups such as the Treatment Advocacy Center cite cost and clinic capacity as the main barriers to LAI antipsychotic use. Payers respond with prior authorisation and step therapy through cheaper oral generics. This is an access ceiling rather than a demand problem, and it defines how fast premium products can spread.
Complex Microsphere Manufacturing — Making a depot is harder than making the drug inside it. PLGA microspheres need aseptic solvent-evaporation or spray-drying lines, tightly controlled polymer grades and in-vitro release tests that can run for weeks per batch. A 2022 review in Pharmaceutics catalogued the scale-up, burst-release and stability problems that delay PLGA product development. Capacity is therefore concentrated in a few brand-owner plants and specialist contract sites. New entrants such as Lupin, through its PrecisionSphere platform, are trying to widen that base, but qualification takes years.
Provider Administration and REMS Burden — A product a patient cannot take at home depends on clinic capacity. Most long-acting injectables and implants must be given by a trained healthcare provider, and several carry Risk Evaluation and Mitigation Strategies. Organon's January 2026 five-year NEXPLANON approval came with a new REMS covering insertion and removal training. Indivior's Sublocade and Teva's subcutaneous depots also run through provider administration. Homecare settings, at 16.2% of 2025 revenue, are forecast to grow at only 3.65% a year, the slowest end-user rate in this report.
Lenacapavir can only change the course of the HIV epidemic if it is affordable and available to everyone who needs it, so the price must come down and generic production must expand.
Where Is the Long-Acting Injectable Pharmaceuticals Market Headed Next?
Generic Lenacapavir for Low-Income Markets — Low prices could turn HIV prevention into the market's largest volume pool. In September 2025 agreements backed by the Gates Foundation, CHAI and Unitaid set generic lenacapavir from Dr. Reddy's and Hetero at about USD 40 per person per year from 2027. That price point opens national programs that cannot fund brand pricing. Gilead's own voluntary licensing keeps it tied to that volume. The opportunity is structural: a high-volume, low-price tier sitting alongside the branded U.S. and European market.
Platform Licensing to Large Pharma — Owning the delivery technology can pay without owning the brand. Medincell's BEPO copolymer depot underpins Teva's Uzedy and the October 2026 WELTRUZA approval, earning milestones and royalties. Camurus has licensed its FluidCrystal lipid depot to Eli Lilly for incretins, and Lupin opened PrecisionSphere to partners in October 2025. Large pharma companies want longer-interval versions of their biggest molecules before patents expire. Expect platform deals to multiply through 2030 as obesity, psychiatry and HIV franchises seek interval extensions.
Correctional and Justice-Setting Treatment — Justice settings need treatments that cannot be diverted or missed. Monthly extended-release buprenorphine removes daily dosing lines and diversion risk, which is why NIDA's JCOIN network has studied its use in jails and prisons. Oregon's Criminal Justice Commission issued an injectable buprenorphine guide in April 2026 for local facilities. Long-acting antipsychotics serve the same population after release. Correctional and public health facilities earned USD 1,279.7 Mn in 2025 and are forecast to reach USD 2,487.8 Mn by 2035.
Asia Pacific Microsphere Capacity — Asia Pacific is turning from buyer into builder. South Korea's G2GBio signed a license deal with a KRW 20 billion investment from Samsung Bioepis's Epis NexLab for long-acting semaglutide microspheres, and Peptron signed a SmartDepot platform evaluation agreement with Eli Lilly in October 2024. Luye Pharma in China and Lupin in India already sell or partner microsphere products. Local capacity lowers cost and speeds approval in the region's fastest-growing markets. G2GBio's Samsung-backed semaglutide program is the regional platform most likely to reach global partners first.
Operational Hurdles in the Long-Acting Injectable Pharmaceuticals Market
Generic Erosion of Legacy Depots — Legacy depots are losing their protection. Generic paliperidone palmitate products are moving toward the U.S. market, and Ipsen's full-year 2025 results reflected lanreotide generic pressure on Somatuline. Brand owners respond by moving patients to longer-interval versions. Structurally, the market rewards interval innovation and penalises franchises that stand still.
Donor Funding Volatility — Public money sets volume in lower-income markets. Long-acting HIV prevention and injectable contraception in Africa depend heavily on PEPFAR, the Global Fund and UNFPA, and policy analysts at CSIS have tracked how changes to U.S. foreign assistance affect the lenacapavir rollout. Any funding cut flows straight into procurement orders. Watch the 2027 shift to generic supply, which should make volumes less sensitive to any single donor.

Long-Acting Injectable Pharmaceuticals Market: The AI Advantage
Release modelling is where machine learning changes long-acting product work. Formulators use models trained on polymer composition, particle size and drug loading to predict in-vitro and in-vivo release curves, which cuts the number of weeks-long release tests a PLGA program needs. Population pharmacokinetic modelling, a long-standing tool, now pairs with these models to support interval extensions, the approach regulators accepted for Otsuka and Lundbeck's bridging-study approval of every-two-months Abilify Asimtufii.
For buyers, the effect is faster arrival of longer-interval and generic depots and lower development risk for platform licensees such as Medincell, Camurus and Lupin. Health systems also apply predictive analytics to flag patients at risk of missing oral doses, which steers depot prescribing toward those who benefit most. Expect model-guided formulation to shorten long-acting development timelines through the forecast horizon.
Long-Acting Injectable Pharmaceuticals Market: Segmentation
The Global Long-Acting Injectable Pharmaceuticals market is segmented by Product Type, Therapeutic Area, Technology, End User.
By Product Type
Implants are the fastest-growing product type, forecast to compound at 15.1% a year and climb from USD 2,781.4 Mn in 2025 to USD 11,348.3 Mn by 2035, as multi-year contraceptive rods, ocular inserts and hormone implants replace monthly dosing schedules. Microspheres lead today with 32.0% of 2025 revenue (USD 4,045.7 Mn). That lead rests on three decades of PLGA microsphere products such as Lupron Depot, Sandostatin LAR and Vivitrol, whose solvent-evaporation manufacturing few generic entrants have managed to copy. In-situ forming depots and gels hold 26.0% (USD 3,287.1 Mn) and suspensions 20.0% (USD 2,528.5 Mn), the latter carried by paliperidone palmitate and aripiprazole products. The implant case has a clear anchor: in January 2026 the FDA extended Organon's NEXPLANON etonogestrel implant to five years of pregnancy prevention, adding two years of protection to every insertion.
Long-Acting Injectable Pharmaceuticals Market: Revenue Split By Product Type (2023–2025, USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| Microspheres | 2,978.0 | 3,534.6 | 4,045.7 |
| In-Situ Forming Depots/Gels | 2,606.5 | 2,766.3 | 3,287.1 |
| Implants | 2,575.0 | 2,663.2 | 2,781.4 |
| Suspensions | 1,821.9 | 2,073.7 | 2,528.5 |

By Therapeutic Area
Ophthalmology, endocrinology and metabolic disease is the fastest-growing therapeutic area, forecast at a 16.46% CAGR from USD 1,011.4 Mn in 2025 to USD 4,643.8 Mn by 2035, as monthly metabolic injectables and sustained-release ocular products move through late-stage pipelines. Pfizer's November 2025 acquisition of Metsera, owner of a monthly injectable GLP-1 candidate, shows how quickly obesity is pulling long-acting technology into a new category. Psychiatric disorders remain the largest area at 33.7% of 2025 revenue (USD 4,258.4 Mn), because relapse in schizophrenia is so often driven by missed oral doses. Johnson & Johnson's paliperidone palmitate franchise, dosed monthly, every three months or every six months, anchors that position. Contraception follows at 26.3% (USD 3,327.2 Mn), oncology at 18.0% and infectious disease at 14.0%.
Long-Acting Injectable Pharmaceuticals Market: Revenue Split By Therapeutic Area (2023–2025, USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| Psychiatric Disorders | 3,123.6 | 3,533.5 | 4,258.4 |
| Contraception | 2,916.6 | 3,122.4 | 3,327.2 |
| Oncology | 1,572.1 | 1,834.8 | 2,275.7 |
| Infectious Disease | 1,711.7 | 1,754.8 | 1,770.0 |
| Ophthalmology, endocrinology and metabolic disease | 657.4 | 792.3 | 1,011.4 |
By Technology
PLGA-based formulations are both the largest and the fastest-growing technology. They held 47.4% of 2025 revenue (USD 5,987.8 Mn) and are forecast to compound at 13.91% a year to USD 22,022.8 Mn by 2035, lifting their share to 62.7%. The polymer's appeal is predictable hydrolysis: formulators can tune release from one month to six, and regulators have reviewed PLGA depots since Lupron Depot reached the U.S. market in 1989. Non-PLGA polymer systems hold 26.6% (USD 3,367.8 Mn), including the copolymer depot behind Teva's Uzedy and the lipid liquid-crystal depots Camurus sells as Brixadi and Oczyesa. Non-polymeric implants (16.0%) and oil-based depot and crystal suspension technologies (10.0%) complete the split. Lupin's October 2025 decision to open its PrecisionSphere microsphere platform to partners points to where new PLGA capacity is coming from.
Long-Acting Injectable Pharmaceuticals Market: Revenue Split By Technology (2023–2025, USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| PLGA-Based | 4,587.2 | 5,105.4 | 5,987.8 |
| Non-PLGA Polymer-Based | 2,196.3 | 2,647.6 | 3,367.8 |
| Non-Polymeric (Implant) | 2,096.1 | 2,123.9 | 2,022.8 |
| Oil-based depot and crystal suspension technologies | 1,101.8 | 1,160.9 | 1,264.3 |
By End User
Hospitals are the fastest-growing end user as well as the largest. They took 43.7% of 2025 revenue (USD 5,522.6 Mn) and are forecast to grow at 13.54% a year to USD 19,665.0 Mn by 2035. Most first injections of long-acting antipsychotics, leuprolide depots and ocular implants happen in inpatient units, hospital outpatient departments and infusion clinics, where trained staff, observation space and cold-chain storage already sit. Specialty pharmacies follow at 30.0% (USD 3,792.8 Mn), handling buy-and-bill logistics and refill timing for maintenance doses. Homecare settings hold 16.2% and correctional and public health facilities 10.1%. Clinic-administered HIV prevention adds hospital and clinic volume: Gilead's twice-yearly Yeztugo, approved by the FDA in June 2025, is given by a healthcare provider as a subcutaneous injection.
Long-Acting Injectable Pharmaceuticals Market: Revenue Split By End User (2023–2025, USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| Hospitals | 3,473.2 | 4,133.1 | 5,522.6 |
| Specialty Pharmacies | 3,025.5 | 3,373.1 | 3,792.8 |
| Homecare Settings | 2,367.1 | 2,324.4 | 2,047.6 |
| Correctional & Public Health Facilities | 1,115.6 | 1,207.2 | 1,279.7 |


Long-Acting Injectable Pharmaceuticals Market: Production & Volume Analysis, 2025
Vectomat Insights estimates that about 92.5 million long-acting doses, counting injections and implant insertions, were administered worldwide in 2025. The volume-value split is wide. Suspensions account for 64.0% of doses, or roughly 59.2 million, because three-monthly DMPA contraceptive injections such as Depo-Provera and Sayana Press ship in very large public-sector volumes at low unit prices, yet the category earns only 20.0% of revenue. Microspheres take 15.0% of doses but 32.0% of value. Across the market, the implied average selling price is about USD 137 per dose, ranging from roughly USD 43 for suspensions to around USD 290-320 for microspheres, depots and implants.
| Metric | 2025 Volume (doses administered (injections and implant insertions)) | Share of Units |
|---|---|---|
| Total doses administered (injections and implant insertions) (2025) | 92,500,000 | 100.0% |
| Microspheres | 13,875,000 | 15.0% |
| In-Situ Forming Depots/Gels | 10,175,000 | 11.0% |
| Implants | 9,250,000 | 10.0% |
| Suspensions | 59,200,000 | 64.0% |
Reference point: UNFPA Kenya — Delivered 450,000 doses of self-injectable DMPA-SC contraceptives to support access to modern contraception (2024-2025). 450,000 doses delivered.
Long-Acting Injectable Pharmaceuticals Market: Competitive Landscape
The Long-Acting Injectable Pharmaceuticals market is moderately concentrated by brand and fragmented by technology. A handful of franchise owners take most of the value, led by Johnson & Johnson in antipsychotics, Gilead and ViiV Healthcare in HIV, and Pfizer and Organon in contraception, while delivery-platform specialists supply the formulation science behind the next wave of launches. Competition is shifting from molecule to dosing interval: six-monthly paliperidone, twice-yearly lenacapavir and five-year implants all compete on how rarely a patient must return to clinic. Key players include Johnson & Johnson, Otsuka Pharmaceutical, Teva Pharmaceuticals, Gilead Sciences, ViiV Healthcare, Pfizer, Organon, Alkermes, Indivior, Ipsen, Camurus, Medincell, Foresee Pharmaceuticals and Lupin, among others.
| Company | HQ Country | Primary Focus | Key Strategy | Notable Recent Action |
|---|---|---|---|---|
| Johnson & Johnson | U.S. | Paliperidone palmitate antipsychotic depots (Invega Sustenna, Trinza, Hafyera) | Move patients to three- and six-month intervals to defend the franchise against generics | Presented new neuropsychiatry portfolio and pipeline data at APA and ASCP in May 2026 |
| Otsuka Pharmaceutical | Japan | Aripiprazole depots with Lundbeck (Abilify Maintena, Abilify Asimtufii) | Extend dosing intervals and indications into bipolar I maintenance | Won Health Canada approval for every-two-months Abilify Asimtufii with Lundbeck in January 2025 |
| Teva Pharmaceuticals | Israel | Subcutaneous antipsychotic depots (Uzedy, WELTRUZA) | Build a branded neuroscience franchise on partnered depot technology | Received FDA approval of once-monthly subcutaneous olanzapine WELTRUZA in October 2026 |
| Gilead Sciences | U.S. | Twice-yearly lenacapavir for HIV prevention (Yeztugo, Yeytuo) | Lead long-acting HIV prevention with tiered global access deals | Announced a lenacapavir access partnership with PAHO for Latin America and the Caribbean in September 2026 |
| ViiV Healthcare | U.K. | Long-acting cabotegravir regimens (Cabenuva, Apretude) | Move from every-two-months to ultra-long-acting dosing of four months or more | Presented ultra-long-acting HIV pipeline data at CROI in February 2026 |
| Pfizer | U.S. | DMPA contraceptive injections (Depo-Provera, Sayana Press) and monthly GLP-1 development | Pair global contraceptive access with entry into long-acting obesity therapy | Completed the acquisition of Metsera and its monthly injectable GLP-1 in November 2025 |
| Organon | U.S. | Contraceptive implant NEXPLANON | Extend label duration and grow women's health franchises | Won FDA approval extending NEXPLANON use to five years in January 2026 |
| Alkermes | Ireland | Aristada aripiprazole lauroxil and Vivitrol naltrexone microspheres | Use long-acting cash flow to fund its neuroscience pipeline | Reported full-year 2025 results and announced a leadership change in February 2026 |
| Indivior | U.S. | Monthly buprenorphine depot Sublocade for opioid use disorder | Make Sublocade the company's main growth driver, including justice settings | Reported third-quarter 2025 results led by Sublocade in October 2025 |
| Ipsen | France | Somatuline lanreotide and Decapeptyl triptorelin depots | Protect its endocrine-oncology base while generics erode lanreotide | Published full-year 2025 results in February 2026 |
| Camurus | Sweden | FluidCrystal lipid depots (Brixadi/Buvidal, Oczyesa) | Combine own brands with platform licensing to large pharma | Received EU marketing authorisation for Oczyesa in acromegaly in July 2025 |
| Medincell | France | BEPO copolymer subcutaneous depot technology | License the platform to partners such as Teva and AbbVie for royalties and milestones | Reported FY2025-26 annual results in June 2026, ahead of partner Teva's WELTRUZA approval |
| Foresee Pharmaceuticals | Taiwan | Ready-to-use leuprolide mesylate depots (CAMCEVI) | 505(b)(2) improvements on established hormone depots | Gained FDA approval of three-month CAMCEVI ETM 21 mg in August 2025 |
| Lupin | India | PrecisionSphere microsphere platform and complex long-acting generics | Partner its microsphere platform to build complex-injectable revenue | Launched a strategic partnership program for PrecisionSphere in October 2025 |
Three strategic themes recur across the 14 profiled companies. Interval extension is the first, from Otsuka's two-month Abilify Asimtufii to ViiV's push past four months. Platform licensing is the second: Medincell, Camurus and Lupin earn through partners rather than their own sales forces. The third is access pricing, where Gilead's Global Fund, PEPFAR and PAHO agreements trade price for volume in lower-income markets.

Supply Chain Dynamics in the Long-Acting Injectable Pharmaceuticals Market
Polymer, lipid and API supply — The chain starts with specialty excipients and active ingredients. Medical-grade PLGA, PEG-PLA copolymers and lipid systems need tight molecular-weight control, because small batch differences change release curves. Platform owners such as Medincell and Camurus control their own formulation chemistry, while Lupin's Nanomi unit and Korean developers such as G2GBio build in-house microsphere know-how. Supplier qualification takes years, which keeps switching costs high and supply concentrated. Key Players: Medincell.
Formulation and sterile manufacturing — Microsphere and depot production is the bottleneck. Solvent-evaporation and spray-drying processes must run aseptically, particle size must stay within narrow limits, and every batch needs in-vitro release testing that can take weeks. This is why so few generic microsphere products have reached the market despite expired patents. Brand owners including Johnson & Johnson and Ipsen run dedicated plants, while Foresee and Lupin compete by simplifying formats into ready-to-use syringes. Key Players: Foresee Pharmaceuticals.
Distribution, administration and access — Most long-acting products are provider-administered, so the final stage runs through hospitals, specialty pharmacies, community mental-health centres and donor-funded clinics. Cold-chain storage, buy-and-bill reimbursement and REMS training shape uptake as much as clinical data. In lower-income markets, procurement agents such as the Global Fund, PEPFAR, PAHO and UNFPA act as the main buyers, as Gilead's November 2025 lenacapavir shipments to Eswatini and Zambia show. Key Players: Gilead Sciences.
Long-Acting Injectable Pharmaceuticals Market: Regional Analysis
North America is the dominant region with 39.0% of 2025 revenue, while Asia Pacific is the fastest-growing, led by South Korea's 13.0% country CAGR. The split is structural: U.S. payers and psychiatric services already reimburse premium antipsychotic, HIV and oncology depots at scale, whereas Asia Pacific is still adding domestic microsphere capacity and moving patients off daily oral therapy.
North America Long-Acting Injectable Pharmaceuticals Market
Psychiatry, HIV and urology clinics in the United States have made long-acting dosing routine rather than exceptional. North America holds 39.0% of the 2025 market, worth USD 4,930.7 Mn, and the United States alone accounts for USD 3,944.6 Mn, growing at 9.6% a year to about USD 9,865.3 Mn by 2035. The approval run has been dense: Gilead's twice-yearly Yeztugo in June 2025, Foresee's CAMCEVI ETM in August 2025, Organon's five-year NEXPLANON label in January 2026 and Teva's WELTRUZA in October 2026. Canada adds Health Canada's January 2025 clearance of Otsuka and Lundbeck's every-two-months Abilify Asimtufii. The principal challenge is price: Yeztugo's list price of roughly USD 28,000 a year has drawn sustained criticism from access groups. For the region, long-acting therapy is now a reimbursement category in its own right, priced and contracted separately from oral generics.
United States Long-Acting Injectable Pharmaceuticals Market Snapshot
| Metric | Value |
|---|---|
| Market Size (2025) | USD 3,944.6 Mn |
| Forecast Value (2035) | USD 9,865.3 Mn |
| CAGR (2026–2035) | 9.6% |

Europe Long-Acting Injectable Pharmaceuticals Market
Europe holds 27.0% of the 2025 market, worth USD 3,413.5 Mn, and Germany is its largest country at USD 955.8 Mn, forecast to grow at 9.2% a year to about USD 2,304.6 Mn by 2035. Regulatory momentum is steady. The European Commission authorised Gilead's twice-yearly Yeytuo for HIV prevention in August 2025, and Camurus won EU approval for its Oczyesa octreotide depot in July 2025. Germany's G-BA completed its benefit assessment of cabotegravir PrEP in August 2025, which shows how national assessment now gates access country by country. Sweden-based Camurus and France-based Ipsen and Medincell give the region an unusually deep bench of delivery-platform developers. The principal challenge is price erosion as lanreotide and paliperidone generics enter. Europe's growth runs about one point below the global 10.76% rate through 2035.
Germany Long-Acting Injectable Pharmaceuticals Market Snapshot
| Metric | Value |
|---|---|
| Market Size (2025) | USD 955.8 Mn |
| Forecast Value (2035) | USD 2,304.6 Mn |
| CAGR (2026–2035) | 9.2% |

Asia Pacific Long-Acting Injectable Pharmaceuticals Market
South Korea is the fastest-growing country market in this report, expanding at 13.0% a year from USD 581.6 Mn in 2025, and it helps make Asia Pacific the fastest-growing region. Asia Pacific holds 23.0% of 2025 revenue, worth USD 2,907.8 Mn. Japan is the largest country at USD 814.2 Mn, forecast to grow at 11.1% a year to about USD 2,332.8 Mn by 2035 under national health insurance coverage of antipsychotic and hormone depots. The region is building its own platforms: Luye Pharma's paliperidone palmitate injection Meibirui was approved in China in June 2024, G2GBio has licensed long-acting semaglutide microsphere technology with Samsung Bioepis backing, and India's Lupin is opening its PrecisionSphere platform to partners. The principal challenge is clinic capacity for psychiatric injections outside major cities. Taiwan's Foresee Pharmaceuticals, whose CAMCEVI ETM won FDA approval in August 2025, shows the region now exports long-acting products as well as consuming them.
Japan Long-Acting Injectable Pharmaceuticals Market Snapshot
| Metric | Value |
|---|---|
| Market Size (2025) | USD 814.2 Mn |
| Forecast Value (2035) | USD 2,332.8 Mn |
| CAGR (2026–2035) | 11.1% |

Latin America Long-Acting Injectable Pharmaceuticals Market
Latin America holds 5.0% of the 2025 market, worth USD 632.1 Mn, with Brazil the largest country through its public health system's purchases of antipsychotic depots and hormonal contraceptives. Pooled procurement is the region's main growth route. In September 2026 Gilead and the Pan American Health Organization announced a partnership giving countries across Latin America and the Caribbean access to twice-yearly lenacapavir through PAHO purchasing mechanisms. Access groups in Brazil have questioned whether the agreed terms go far enough, which points to the principal challenge: public budgets rather than clinical demand set the pace. Expect long-acting HIV prevention to become the region's fastest-growing therapeutic pool over the forecast horizon.
The Middle East Long-Acting Injectable Pharmaceuticals Market
The Middle East accounts for 3.1% of 2025 revenue, worth USD 386.0 Mn, concentrated in Saudi Arabia, the UAE and Israel. GCC hospital groups buy leuprolide and octreotide depots for oncology and endocrine care, while long-acting antipsychotics are gaining ground as psychiatric services expand under national health transformation programs. Israel matters beyond its size: Teva, headquartered there, now markets two subcutaneous antipsychotic depots, Uzedy and WELTRUZA. The principal challenge is dependence on imported finished products, which keeps prices high and supply tied to European and U.S. manufacturing. In practice, the region is a hospital-tender market in which registration with national regulators such as the Saudi FDA decides which brands can compete.
Africa Long-Acting Injectable Pharmaceuticals Market
Africa holds 2.9% of 2025 revenue, worth USD 372.6 Mn, but it carries far more volume than value because injectable contraception and HIV prevention reach patients at donor-negotiated prices. South Africa's SAHPRA approved twice-yearly lenacapavir in October 2025, and the first shipments reached Eswatini and Zambia in November 2025 under Global Fund and PEPFAR commitments covering up to 2 million people each. Self-injected DMPA-SC is the other pillar: UNFPA delivered 450,000 doses of self-injectable contraceptives in Kenya alone. The principal challenge is funding concentration, since changes to U.S. foreign assistance flow straight into procurement volumes. Generic lenacapavir from Dr. Reddy's and Hetero, priced at about USD 40 per person per year from 2027, is the next named supply milestone.


Full Country Coverage
| Region | Countries Covered |
|---|---|
| North America | The U.S., Canada, Mexico |
| Europe | Germany, France, U.K., Italy, Spain, Russia, BENELUX, Sweden, Denmark, Poland, Austria, Rest of Europe |
| Asia Pacific | China, Japan, India, South Korea, Australia, Thailand, Indonesia, Vietnam, Malaysia, Philippines, Taiwan, Rest of Asia Pacific |
| Latin America | Brazil, Argentina, Colombia, Chile, Peru, Rest of Latin America |
| The Middle East | GCC (Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, Oman), Israel, Turkey, Iran, Rest of Middle East |
| Africa | South Africa, Egypt, Nigeria, Algeria, Morocco, Rest of Africa |
Note: Country-level market sizing, historical data, and forecasts available for all geographies listed. Custom regional add-ons available — contact sales@vectomatinsights.com
Long-Acting Injectable Pharmaceuticals Market: Regulatory and Government Backing
Public health/safety program — Donor programs are building the largest volume channel for long-acting HIV prevention, with the Global Fund and PEPFAR each committing to reach up to 2 million people with twice-yearly lenacapavir. (PEPFAR and The Global Fund lenacapavir access agreements)
Reimbursement/funding initiative — Pooled regional purchasing lowers the price barrier for middle-income governments; PAHO opened a lenacapavir access route for Latin America and the Caribbean in September 2026. (PAHO Strategic Fund)
Regulatory-approval program — Regulators are accepting longer dosing intervals and new delivery formats, from the FDA's five-year NEXPLANON label to the EU's centralised authorisation of twice-yearly Yeytuo. (EMA centralised marketing authorisation procedure)
Health-technology assessment — National benefit assessments decide the price premium a long-acting product can hold over oral therapy; Germany's G-BA ruled on cabotegravir PrEP in August 2025. (G-BA early benefit assessment (AMNOG))
Long-Acting Injectable Pharmaceuticals Market: Latest Industry Moves
Recent activity clusters around longer dosing intervals and access deals: five of the six moves below are regulatory approvals, and the sixth is a platform partnering step aimed at the next approval wave.
| Date | Company | Type | Description | Market Impact |
|---|---|---|---|---|
| Jun 2025 | Gilead Sciences | Regulatory | The FDA approved Yeztugo (lenacapavir), the first twice-yearly injectable option for HIV pre-exposure prophylaxis. [source] | Opens a new provider-administered HIV prevention category and sets the benchmark for six-month dosing. |
| Jul 2025 | Camurus | Regulatory | The European Commission granted marketing authorisation for Oczyesa, a FluidCrystal octreotide subcutaneous depot, for acromegaly. [source] | Brings a non-PLGA lipid depot into a field long held by microsphere and lanreotide products. |
| Aug 2025 | Foresee Pharmaceuticals | Regulatory | The FDA approved CAMCEVI ETM 21 mg, a ready-to-use three-month leuprolide mesylate depot for advanced prostate cancer. [source] | Adds a longer-interval, no-mixing format to the oncology hormone depot segment. |
| Oct 2025 | Lupin | Partnership | Lupin launched a strategic partnership program to open its PrecisionSphere long-acting microsphere platform to external developers. [source] | Widens access to scarce PLGA microsphere development and manufacturing capacity. |
| Jan 2026 | Organon | Regulatory | The FDA approved a supplemental NDA extending NEXPLANON (etonogestrel implant 68 mg) use to five years, with a new REMS program. [source] | Lengthens the implant replacement cycle and strengthens the case for implants as the fastest-growing product type. |
| Oct 2026 | Teva Pharmaceuticals | Regulatory | The FDA approved WELTRUZA, the first once-monthly subcutaneous olanzapine injectable for adults with schizophrenia, built on Medincell technology. [source] | Adds olanzapine to the subcutaneous antipsychotic depot class without post-injection monitoring. |
Research Methodology
Overall approach
Vectomat Insights sized the Long-Acting Injectable Pharmaceuticals market by combining a bottom-up model, built from product-level revenue for branded depots, implants and suspensions, with a top-down check against company-reported long-acting franchise sales and regional pharmaceutical spending. Each product was mapped to one product type, therapeutic area, technology and end user so that the four segmentation dimensions reconcile to the same 2025 total of USD 12,642.7 Mn.
Primary research
Analysts held structured interviews with formulation scientists at depot platform companies, hospital and community mental-health pharmacists, specialty pharmacy operators, HIV program managers and procurement staff at public-sector buyers. The interviews tested dosing-interval adoption, provider-administration capacity, tender pricing for contraceptive and HIV products, and the realistic timing of generic microsphere entry.
Secondary research
Secondary sources include FDA and EMA approval records, company annual reports and earnings materials (Johnson & Johnson, Gilead Sciences, Teva, Alkermes, Ipsen, Camurus, Medincell), WHO, UNAIDS, Global Fund, PEPFAR and PAHO program announcements, national benefit assessments such as Germany's G-BA resolutions, and peer-reviewed literature on PLGA formulation and antipsychotic adherence.
Data validation
Segment and regional values were reconciled to the base-year total, and each featured country was checked against its regional total (for example, the U.S. at USD 3,944.6 Mn within North America's USD 4,930.7 Mn). Franchise-level estimates were cross-checked against reported company revenue, and forecast growth rates by segment were tested for consistency with the overall 10.76% CAGR.
Market Coverage Definitions
How this report defines the scope of the Long-Acting Injectable Pharmaceuticals Market: what each segment and sub-segment includes.
| Segment | Market Coverage Definition |
|---|---|
| By Product Type | Segments the market by dosage form, covering microspheres, in-situ forming depots and gels, implants, and suspensions. |
| By Therapeutic Area | Segments the market by clinical use, covering psychiatric disorders, contraception, oncology, infectious disease, and other therapeutic areas. |
| By Technology | Segments the market by the delivery platform used to achieve sustained release, covering PLGA-based, non-PLGA polymer-based, and non-polymeric implant technologies, and other approaches. |
| By End User | Segments the market by the setting where products are administered, covering hospitals, specialty pharmacies, homecare settings, and correctional and public health facilities. |
By Product Type
| Sub-Segment | Market Coverage Definition |
|---|---|
| Microspheres | Biodegradable polymer microparticles that encapsulate a drug and release it over weeks to months after injection, the largest product category given their wide use in psychiatric and oncology formulations. |
| In-Situ Forming Depots & Gels | Liquid formulations that solidify into a depot after subcutaneous or intramuscular injection, releasing drug as the depot gradually degrades. |
| Implants | Solid devices placed subcutaneously that release drug over months to years, most widely used in long-term contraception. |
| Suspensions | Crystalline or particulate drug suspensions injected intramuscularly or subcutaneously, relying on slow dissolution at the injection site for extended release. |
By Therapeutic Area
| Sub-Segment | Market Coverage Definition |
|---|---|
| Psychiatric Disorders | Long-acting injectable antipsychotics used to maintain treatment adherence in schizophrenia and bipolar I disorder, the largest therapeutic area given the volume of branded and generic risperidone, olanzapine, and related products in use. |
| Contraception | Injectable and implantable hormonal contraceptives providing pregnancy prevention ranging from three months to several years per administration. |
| Oncology | Long-acting injectable hormone therapies, including leuprolide and related formulations, used primarily in advanced prostate cancer management. |
| Infectious Disease | Long-acting injectable antiretrovirals and other anti-infective formulations, including pre-exposure prophylaxis products dosed as infrequently as twice yearly. |
| Others | Additional therapeutic uses of long-acting injectable formulations outside the primary categories above. |
By Technology
| Sub-Segment | Market Coverage Definition |
|---|---|
| PLGA-Based | Formulations built on poly(lactic-co-glycolic acid) polymer technology, the most widely used biodegradable platform for microsphere and depot long-acting injectables. |
| Non-PLGA Polymer-Based | Formulations using alternative biodegradable or non-biodegradable polymers, including copolymer-based in-situ depot technologies. |
| Non-Polymeric (Implant) | Implant-based formulations that do not rely on a degrading polymer matrix to control release, instead using a solid rod or reservoir device. |
| Others | Additional delivery technologies used to achieve sustained release in long-acting injectable products. |
By End User
| Sub-Segment | Market Coverage Definition |
|---|---|
| Hospitals | Hospital-based administration of long-acting injectables, particularly for treatment initiation and dose titration under clinical supervision. |
| Specialty Pharmacies | Pharmacies that manage procurement, cold-chain storage, and distribution of long-acting injectable products to prescribing clinics. |
| Homecare Settings | Self-administration or caregiver-administration of long-acting injectable products, including subcutaneous contraceptives, outside a clinical setting. |
| Correctional & Public Health Facilities | Administration of long-acting injectable antipsychotics and contraceptives within correctional systems and public health programs, where adherence support is a particular priority. |
Market Assessment Framework
The four-step framework used to size and validate the Long-Acting Injectable Pharmaceuticals market.
- 1
Bottom-Up Approach
Market size is built from treated-patient volumes across psychiatric disorders, contraception, oncology, and infectious disease, combined with average per-patient dosing frequency and price for microspheres, in-situ forming depots and gels, implants, and suspensions, then aggregated across technologies and regions to arrive at total market value.
- 2
Volume-Based Assessment
Dose volume is estimated from disclosed prescription and shipment data at branded and generic long-acting injectable manufacturers, cross-checked against hospital, specialty pharmacy, and correctional and public health facility procurement volumes.
- 3
Price & Revenue Benchmarking
Average selling prices are benchmarked across product types and delivery technologies, including PLGA-based, non-PLGA polymer-based, and non-polymeric implant formulations, using payer reimbursement data, disclosed contract values, and reported segment revenue from major pharmaceutical manufacturers.
- 4
Market Validation & Triangulation
Preliminary estimates are validated through structured interviews with prescribing clinicians, specialty pharmacy directors, and manufacturer executives, and cross-checked against company financial disclosures, regulatory filings, and secondary research to reconcile top-down and bottom-up estimates within an acceptable variance.
Specialized Analyst Insights
Gilead's FDA approval of Yeztugo as the first twice-yearly injectable for HIV pre-exposure prophylaxis sets a new benchmark for dosing interval in the infectious disease segment of this market, where most prior long-acting options required monthly or bimonthly administration. A twice-yearly product changes the adherence conversation for prevention programs in a way that formulations dosed every few weeks cannot, and it is likely to put pressure on other infectious disease developers to pursue longer dosing intervals rather than incremental extensions.
Foresee's CAMCEVI ETM 21 mg approval, licensed to Accord BioPharma for U.S. commercialization, illustrates a common structure in this market where a formulation developer retains the underlying delivery technology while a larger specialty pharmaceutical company handles distribution and market access. This licensing pattern lets smaller formulation-focused companies continue developing new long-acting candidates without building their own commercial infrastructure.
Lupin's decision to open its PrecisionSphere platform to outside partners, rather than using it only for its own pipeline, signals a shift toward long-acting injectable delivery technology itself becoming a licensable asset, similar to how Medincell's SteadyTeq technology underpins long-acting injectable programs at Teva. As more companies pursue this platform-licensing model, the competitive advantage in this market may increasingly sit with firms that control proven delivery technology rather than those that only develop individual drug candidates.
The approvals for NEXPLANON's extended five-year use and for Teva and Medincell's TEV-'749 both illustrate how regulatory attention in this market has shifted toward the administration burden of long-acting injectables, not just their efficacy. NEXPLANON's new Risk Evaluation and Mitigation Strategy tightens who may insert and remove the implant, while TEV-'749 is being positioned specifically to avoid the monitoring and REMS requirements attached to existing long-acting olanzapine injections. Together they suggest that reducing administration and monitoring burden is becoming as important a differentiator in this market as dosing interval itself.
Regional Regulations
Regulatory authorities and requirements across 9 jurisdictions
| Region | Key Regulatory Authorities / Frameworks | Government Regulations and Regulatory Considerations |
|---|---|---|
| North AmericaU.S. | U.S. FDA | Long-acting injectable drugs are regulated as new drug or abbreviated new drug applications depending on whether they are branded or generic, with some products, including certain implant formulations, subject to Risk Evaluation and Mitigation Strategy requirements covering administration and removal. |
| Europe | European Medicines Agency | Long-acting injectable products marketed in Europe require centralized or national marketing authorization, with risk management plans required for products carrying administration-related safety considerations. |
| Asia PacificJapan | MHLW, PMDA | Long-acting injectable products in Japan are regulated under the Pharmaceuticals and Medical Devices Act, with domestic clinical data often required to support approval. |
| Asia PacificChina | NMPA | China's NMPA regulates long-acting injectable drugs as pharmaceutical products, with a growing number of domestic generic and novel formulations entering review. |
| Asia PacificIndia | CDSCO | Long-acting injectable products in India are regulated by the CDSCO, with Indian manufacturers increasingly developing generic long-acting injectable antipsychotics and contraceptives for both domestic and export markets. |
| Asia PacificSouth Korea | MFDS | South Korea's Ministry of Food and Drug Safety regulates long-acting injectable products as pharmaceutical drugs, with domestic approval pathways for both branded and generic formulations. |
| Latin AmericaBrazil | ANVISA | Long-acting injectable products in Brazil are regulated as pharmaceutical drugs by ANVISA, with growing public health program use of injectable contraceptives. |
| Middle East | National health product regulatory authorities, GCC frameworks | Long-acting injectable product regulation continues to develop across the region alongside growing specialty pharmacy infrastructure and mental health program investment. |
| Global / International | WHO Prequalification Programme | WHO prequalification supports access to long-acting injectable contraceptives and other essential formulations in public health programs across lower-income countries, alongside national regulatory approval. |
Strategic Activities
5 strategic developments shaping the Long-Acting Injectable Pharmaceuticals Market
| Date | Company / Companies | Development Type | Development and Impact on Market |
|---|---|---|---|
| Jun 2025 | Gilead Sciences | Regulatory Approval | The FDA approved Yeztugo (lenacapavir), the first twice-yearly injectable option for HIV pre-exposure prophylaxis, offering up to six months of protection from a single subcutaneous dose. The approval gave clinicians an infectious-disease long-acting injectable option requiring only two administrations per year, compared with daily oral regimens or more frequent injectable alternatives. [source] |
| Aug 2025 | Foresee Pharmaceuticals, Accord BioPharma | Regulatory Approval | The FDA approved CAMCEVI ETM 21 mg, a ready-to-use leuprolide mesylate formulation dosed once every three months for advanced prostate cancer. A Phase 3 study of 144 patients reported that 97.9% met the primary efficacy endpoint. The product is exclusively licensed to Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, for commercialization. [source] |
| Oct 2025 | Lupin, Nanomi B.V. | Platform Partnership | Lupin opened its PrecisionSphere long-acting injectable platform, developed by its subsidiary Nanomi B.V., to partnership with other drug developers seeking to extend product life cycles through sustained-release formulations. The platform's first product had already received FDA approval, and Lupin said broader partner adoption could extend the approach across additional therapeutic areas. [source] |
| Jan 2026 | Organon | Regulatory Approval | The FDA approved a supplemental application extending NEXPLANON's approved duration of use from three years to five years, based on a U.S. study of 399 women that reported no pregnancies in years four and five. The FDA also required a new Risk Evaluation and Mitigation Strategy restricting insertion and removal to certified healthcare providers, beginning February 23, 2026. [source] |
| Feb 2026 | Teva, Medincell | Regulatory Filing | The FDA accepted Teva and Medincell's New Drug Application for TEV-'749, a once-monthly subcutaneous olanzapine extended-release injectable for schizophrenia built on Medincell's SteadyTeq copolymer technology. The Phase 3 SOLARIS trial reported efficacy comparable to oral olanzapine with no post-injection delirium or sedation events, which the companies said could allow the product to avoid the REMS and monitoring requirements attached to existing long-acting olanzapine injections. [source] |
Related Analysis
Blog · PharmaceuticalsIn Long-Acting Injectables, the Real Competition Is Over Dosing Interval
From a twice-yearly HIV prevention shot to a five-year contraceptive implant, approvals across the past eight months show manufacturers competing less on which drug they deliver and more on how rarely a patient has to come back.
Read the article →Table of Contents: Long-Acting Injectable Pharmaceuticals Market Report
12 chapters · 98 tables & 71 figures. Expand a chapter to see its sub-sections.
Executive Summary
- Market Snapshot, 2025 and 2035
- Key Findings by Segment and Region
Research Methodology
- Research Approach
- Market Size Estimation and Data Triangulation
Market Overview
- Market Definition and Scope
- Value Chain and Supply Chain Analysis
- Pricing Analysis by Product Type
Market Dynamics
- Drivers
- Restraints
- Opportunities
- Challenges
- Role of AI in Long-Acting Formulation
Long-Acting Injectable Pharmaceuticals Market, By Product Type
- Market Size and Share by Product Type, 2023–2035
Long-Acting Injectable Pharmaceuticals Market, By Therapeutic Area
- Market Size and Share by Therapeutic Area, 2023–2035
Long-Acting Injectable Pharmaceuticals Market, By Technology
- Market Size and Share by Technology, 2023–2035
Long-Acting Injectable Pharmaceuticals Market, By End User
- Market Size and Share by End User, 2023–2035
Long-Acting Injectable Pharmaceuticals Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- The Middle East
- Africa
Competitive Landscape
- Market Share Analysis
- Strategic Developments, 2024–2026
Company Profiles
- Johnson & Johnson
- Otsuka Pharmaceutical
- Teva Pharmaceuticals
- Gilead Sciences
- ViiV Healthcare
- Pfizer
- Organon
- Alkermes
- Indivior
- Ipsen
- Camurus
- Medincell
- Foresee Pharmaceuticals
- Lupin
Appendix
- Abbreviations
- Disclaimer
List of Tables (selected)
- Global Long-Acting Injectable Pharmaceuticals Market Size, 2023–2035 (USD Million)
- Long-Acting Injectable Pharmaceuticals Market: Revenue Split By Product Type (2023–2025, USD Million)
- Long-Acting Injectable Pharmaceuticals Market: Revenue Split By Therapeutic Area (2023–2025, USD Million)
- Long-Acting Injectable Pharmaceuticals Market: Revenue Split By Technology (2023–2025, USD Million)
- Long-Acting Injectable Pharmaceuticals Market: Revenue Split By End User (2023–2025, USD Million)
- Long-Acting Injectable Pharmaceuticals Production & Volume, By Product Type, 2025 (doses administered)
- North America Long-Acting Injectable Pharmaceuticals Market Size, 2023–2035 (USD Million)
- Europe Long-Acting Injectable Pharmaceuticals Market Size, 2023–2035 (USD Million)
- Asia Pacific Long-Acting Injectable Pharmaceuticals Market Size, 2023–2035 (USD Million)
- Latin America Long-Acting Injectable Pharmaceuticals Market Size, 2023–2035 (USD Million)
- The Middle East Long-Acting Injectable Pharmaceuticals Market Size, 2023–2035 (USD Million)
- Africa Long-Acting Injectable Pharmaceuticals Market Size, 2023–2035 (USD Million)
- United States Long-Acting Injectable Pharmaceuticals Market Snapshot, 2025–2035
- Germany Long-Acting Injectable Pharmaceuticals Market Snapshot, 2025–2035
- Japan Long-Acting Injectable Pharmaceuticals Market Snapshot, 2025–2035
- Key Companies: HQ, Primary Focus, Strategy and Recent Action
- Recent Developments, 2025–2026
List of Figures (selected)
- Long-Acting Injectable Pharmaceuticals Market Size, 2025–2035
- Long-Acting Injectable Pharmaceuticals Market Share by Region, 2025
- Long-Acting Injectable Pharmaceuticals Market Share, By Product Type, 2025
- Long-Acting Injectable Pharmaceuticals Market Share, By End User, 2025
- Long-Acting Injectable Pharmaceuticals Market: Segmentation Overview
- Long-Acting Injectable Pharmaceuticals Market: Product Type Mix by Region
- Long-Acting Injectable Pharmaceuticals Market: DROC Analysis
- Long-Acting Injectable Pharmaceuticals Market: Competitive Landscape
- Long-Acting Injectable Pharmaceuticals Market at a Glance
- United States Long-Acting Injectable Pharmaceuticals Market Size Trend
- Germany Long-Acting Injectable Pharmaceuticals Market Size Trend
- Japan Long-Acting Injectable Pharmaceuticals Market Size Trend
You May Also Be Interested In
Advanced Drug Delivery Technologies Market
Same delivery-platform value chain and formulation buyers
Oligonucleotide Therapeutics Market
Overlapping pharma R&D and business development buyers
PublishedRNA Therapeutics Market
Adjacent specialty pharmaceutical pipelines and partners
Healthcare Cold Chain Packaging Market
Supply-chain link for temperature-sensitive depots and suspensions
All VMI market research reports available in PDF. Contact sales@vectomatinsights.com
Frequently Asked Questions
How big is the Long-Acting Injectable Pharmaceuticals market in 2025?
The Global Long-Acting Injectable Pharmaceuticals market stood at USD 12,642.7 Mn in 2025 and is projected to reach USD 35,129.3 Mn by 2035 at a 10.76% CAGR. Psychiatric disorders account for the largest therapeutic share at 33.7%, followed by contraception at 26.3% and oncology at 18.0%, according to Vectomat Insights.
Which product type grows fastest in long-acting injectables?
Implants are the fastest-growing product type, forecast to compound at 15.1% a year from USD 2,781.4 Mn in 2025 to USD 11,348.3 Mn by 2035. Longer labels such as Organon's five-year NEXPLANON approval in January 2026 and sustained-release ocular and hormone implants drive the gain, while microspheres remain the largest type at 32.0%, according to Vectomat Insights.
Why do PLGA-based formulations dominate the technology split?
PLGA-based formulations held 47.4% of 2025 revenue because the polymer degrades predictably, letting developers tune release from one to six months, and regulators have reviewed PLGA depots since 1989. The segment is forecast to grow at 13.91% a year to USD 22,022.8 Mn by 2035, reaching 62.7% of the market. Lupin's PrecisionSphere program is adding partner capacity, according to Vectomat Insights.
What is restraining long-acting injectable adoption?
Three factors slow adoption: premium pricing, with Yeztugo listed at about USD 28,000 a year in the U.S.; complex aseptic microsphere manufacturing that limits capacity and generic entry; and provider-administration and REMS requirements, which keep homecare growth to 3.65% a year, the slowest end-user rate. Generic erosion of older depots adds price pressure, according to Vectomat Insights.
Which end user leads the long-acting injectables market?
Hospitals lead with 43.7% of 2025 revenue (USD 5,522.6 Mn) and are also the fastest-growing end user at 13.54% a year, because initiation doses, implant insertions and provider-administered HIV prevention need trained staff and observation space. Specialty pharmacies follow at 30.0%. Homecare settings hold 16.2% and correctional and public health facilities 10.1%, according to Vectomat Insights.
What research methodology does the VMI Long-Acting Injectable Pharmaceuticals report use?
VMI combines a bottom-up model built from product-level revenue for branded depots, implants and suspensions with a top-down check against reported company franchise sales. Interviews with formulation scientists, pharmacists and public-sector buyers test the assumptions, and segment, regional and country values are reconciled to the USD 12,642.7 Mn base-year total. Country values are checked against regional totals, according to Vectomat Insights.
Which companies are expanding long-acting platforms through partnerships?
Medincell licenses its copolymer depot to Teva, which won FDA approval for WELTRUZA in October 2026; Camurus signed a FluidCrystal incretin deal with Eli Lilly in June 2025; and Lupin opened its PrecisionSphere microsphere platform to partners in October 2025. Gilead has also signed access deals with the Global Fund, PEPFAR and PAHO. These deals trade price for reach, according to Vectomat Insights.
Access the Complete Long-Acting Injectable Pharmaceuticals Market Report
300+ pages | 98 tables & 71 figures | 2026–2035 | All 6 regions | PDF
Contact: sales@vectomatinsights.com
About Vectomat Insights
Vectomat Insights is an independent market research firm. Our analysts build every market model in-house, from company revenues, government and regulatory data, and interviews with industry participants, and each report is reviewed by a senior analyst and fact-checked before publication.
Contact: Vectomat Insights | Email: sales@vectomatinsights.com | Website: www.vectomatinsights.com
Request a free sample
Ready to go deeper? Request a free sample of the VMI Long-Acting Injectable Pharmaceuticals Report — preview key data tables, segmentation depth, and regional forecasts before purchasing.
About this report
Get a free sample of this report
Long-Acting Injectable Pharmaceuticals Market